What does this research mean for the field?

The IRG1/itaconate axis suppresses lung tumor growth and transforms pro-tumor macrophages into anti-tumor macrophages by inhibiting glucose-6-phosphate dehydrogenase (G6PD) activity in the pentose phosphate pathway. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research investigates the role of IRG1 and itaconate in regulating tumor-associated macrophages and their metabolic effects on lung cancer development.

June 6, 2026Cell Metabolism2 citationsOpen Access

IRG1/Itaconate Modulates Macrophage and Tumor Metabolism via G6PD Inhibition

IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition

View Full Paper

Ask AI

Bookmark

Authors

SMSiavash Mansouri GHGolnaz Hesami AAAnoop Ambikan

Discussion

Member takes

Overview

Randomized trial explores IRG1/itaconate's role in altering metabolism in lung tumors, suggesting potential therapies.

Key Points

This research investigates the role of IRG1 and itaconate in regulating tumor-associated macrophages and their metabolic effects on lung cancer development.
Utilized spatial metabolomics to examine itaconate levels in tumor versus non-tumor tissue.
Employed single-cell RNA sequencing to identify IRG1 expression in macrophages from human and mouse lung tumors.
Assessed the impact of IRG1 knockout and itaconate analog on lung tumor growth using various in vitro and in vivo models.
Itaconate levels are significantly lower in lung tumor regions compared to adjacent non-tumor tissue.
IRG1 depletion in macrophages leads to increased tumor growth in multiple lung cancer models.
Treatment with 4-octyl itaconate reduces tumor growth across in vitro, in vivo, and ex vivo conditions.

Cite This Study

Mansouri et al. (2026) studied this question.

synapsesocial.com/papers/6a23b96a71a5da9775e75638 https://doi.org/10.1016/j.cmet.2026.05.005

View Full Paper

Ask AI

Bookmark

June 6, 2026Cell Metabolism2 citationsOpen Access

IRG1/Itaconate Modulates Macrophage and Tumor Metabolism via G6PD Inhibition

IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition

View Full Paper

Ask AI

Bookmark

Authors

SMSiavash Mansouri GHGolnaz Hesami AAAnoop Ambikan

Discussion

Member takes

Overview

Randomized trial explores IRG1/itaconate's role in altering metabolism in lung tumors, suggesting potential therapies.

Key Points

This research investigates the role of IRG1 and itaconate in regulating tumor-associated macrophages and their metabolic effects on lung cancer development.
Utilized spatial metabolomics to examine itaconate levels in tumor versus non-tumor tissue.
Employed single-cell RNA sequencing to identify IRG1 expression in macrophages from human and mouse lung tumors.
Assessed the impact of IRG1 knockout and itaconate analog on lung tumor growth using various in vitro and in vivo models.
Itaconate levels are significantly lower in lung tumor regions compared to adjacent non-tumor tissue.
IRG1 depletion in macrophages leads to increased tumor growth in multiple lung cancer models.
Treatment with 4-octyl itaconate reduces tumor growth across in vitro, in vivo, and ex vivo conditions.

Cite This Study

Mansouri et al. (2026) studied this question.

synapsesocial.com/papers/6a23b96a71a5da9775e75638 https://doi.org/10.1016/j.cmet.2026.05.005

View Full Paper

Ask AI

Bookmark